Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer

摘要

Background:KRAS p.G12C mutation occurs in approximately 1 to 2%of pancreatic cancers.The safety and efficacy of sotorasib,a KRAS G12C inhibitor,in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown.Methods:We conducted a single-group,phase 1-2 trial to assess the safety and efficacy of sotorasib treatment in patients with KRAS p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy.